{
    "1": {
        "question": "What is the primary receptor involved in mediating the psychedelic effects as discussed in the article?",
        "options": {
            "A": "5-HT2B receptor",
            "B": "5-HT2C receptor",
            "C": "5-HT2A receptor",
            "D": "Dopamine D2 receptor",
            "E": "Alpha-1 adrenergic receptor",
            "F": "I don't know"
        }
    },
    "2": {
        "question": "The activation of which signaling pathway is primarily associated with psychedelic potential according to the findings?",
        "options": {
            "A": "Gq/11 signaling pathway",
            "B": "Gi/o signaling pathway",
            "C": "G12/13 signaling pathway",
            "D": "Gs signaling pathway",
            "E": "\u03b2-arrestin2 signaling pathway",
            "F": "I don't know"
        }
    },
    "3": {
        "question": "What was the effect of disruptors of Gq-PLC signaling on the head-twitch response (HTR)?",
        "options": {
            "A": "Increased HTR",
            "B": "No change in HTR",
            "C": "Attenuated HTR",
            "D": "Increased anxiety in mice",
            "E": "Caused behavioral depression",
            "F": "I don't know"
        }
    },
    "4": {
        "question": "What determines the psychedelic potential of 5-HT2A agonists, as highlighted in the article?",
        "options": {
            "A": "\u03b2-arrestin2 recruitment efficacy",
            "B": "Gq recruitment efficacy",
            "C": "5-HT2B receptor efficacy",
            "D": "LSD-like structure similarity",
            "E": "Serotonin reuptake inhibition",
            "F": "I don't know"
        }
    },
    "5": {
        "question": "Which compound was specifically mentioned as a non-psychedelic partial agonist in the study?",
        "options": {
            "A": "Psilocin",
            "B": "DMT",
            "C": "LSD",
            "D": "Lisuride",
            "E": "25I-NBOMe",
            "F": "I don't know"
        }
    },
    "6": {
        "question": "What characteristic did \u03b2-arrestin-biased 5-HT2A receptor agonists exhibit?",
        "options": {
            "A": "Inducing psychedelic effects",
            "B": "Increasing anxiety in mice",
            "C": "Blocking psychedelic effects",
            "D": "Enhancing serotonin release",
            "E": "Potentiating dopamine release",
            "F": "I don't know"
        }
    },
    "7": {
        "question": "What method was used by the researchers to measure 5-HT2A receptor transducer engagement?",
        "options": {
            "A": "CT Imaging",
            "B": "Bioluminescence resonance energy transfer (BRET)",
            "C": "EKG Monitoring",
            "D": "Ultrasound Imaging",
            "E": "Mass Spectrometry",
            "F": "I don't know"
        }
    },
    "8": {
        "question": "Which compound from the phenethylamine class was identified as having high 5-HT2A receptor affinity?",
        "options": {
            "A": "25CN-NBOH",
            "B": "Mescaline",
            "C": "25N-NBI",
            "D": "Amphetamine",
            "E": "MDMA",
            "F": "I don't know"
        }
    },
    "9": {
        "question": "What was the significance of the hammet \u03c3 constants in the study?",
        "options": {
            "A": "Determining melting point",
            "B": "Predicting solubility",
            "C": "Establishing binding affinity",
            "D": "Defining color properties",
            "E": "Estimating toxicity",
            "F": "I don't know"
        }
    },
    "10": {
        "question": "What kind of correlation was found between 5-HT2A receptor Gq-efficacy and head-twitch response magnitude?",
        "options": {
            "A": "Negative correlation",
            "B": "No correlation",
            "C": "Positive correlation",
            "D": "U-shaped correlation",
            "E": "J-shaped correlation",
            "F": "I don't know"
        }
    },
    "11": {
        "question": "Which amino acid residue was identified as key to 5-HT2A R ligand biased-agonist activity?",
        "options": {
            "A": "Asp156",
            "B": "Gly145",
            "C": "W336",
            "D": "Ser214",
            "E": "Tyr240",
            "F": "I don't know"
        }
    },
    "12": {
        "question": "Which of the following effects is attributed to \u03b2-arrestin-biased agonists?",
        "options": {
            "A": "Psychedelic-like behavior induction",
            "B": "Enhanced Gq-effector engagement",
            "C": "Receptor downregulation and tachyphylaxis",
            "D": "Stimulation of serotonin synthesis",
            "E": "Blockade of dopaminergic pathways",
            "F": "I don't know"
        }
    },
    "13": {
        "question": "What experimental animal model was used to assess psychedelic potential?",
        "options": {
            "A": "Rats",
            "B": "Cats",
            "C": "Guinea pigs",
            "D": "Male mice",
            "E": "Zebrafish",
            "F": "I don't know"
        }
    },
    "14": {
        "question": "Which hallmark behavioral measure was used to predict psychedelic effects?",
        "options": {
            "A": "Locomotor activity",
            "B": "Tail suspension test",
            "C": "Forced swim test",
            "D": "Head-twitch response (HTR)",
            "E": "Marble-burying behavior",
            "F": "I don't know"
        }
    },
    "15": {
        "question": "What finding does the threshold level of 5-HT2A R Gq-efficacy explain?",
        "options": {
            "A": "Why lisuride is non-psychedelic",
            "B": "Why psilocybin is potent",
            "C": "Why DMT affects serotonin",
            "D": "The affinity of LSD to dopamine receptors",
            "E": "The solubility of phenethylamines",
            "F": "I don't know"
        }
    },
    "16": {
        "question": "What do \u03b2-arrestin2-biased agonists fail to induce?",
        "options": {
            "A": "Mood enhancement",
            "B": "Increased appetite",
            "C": "The head-twitch response",
            "D": "Neuroinflammation",
            "E": "Weight gain",
            "F": "I don't know"
        }
    },
    "17": {
        "question": "What role did molecular docking play in the study?",
        "options": {
            "A": "Assessed visual perception changes",
            "B": "Evaluated ligand-binding modes",
            "C": "Measured heart rates in mice",
            "D": "Assessed serotonin levels in blood",
            "E": "Estimated water solubility of ligands",
            "F": "I don't know"
        }
    },
    "18": {
        "question": "What impact did the addition of a 3-methyl group have on the 5-HT2A receptor ligands?",
        "options": {
            "A": "Increased \u03b2-arrestin recruitment",
            "B": "Reduced Gq efficacy",
            "C": "Enhanced psychedelic effect",
            "D": "Increased serotonin release",
            "E": "Enhanced dopamine release",
            "F": "I don't know"
        }
    },
    "19": {
        "question": "What is the potential therapeutic benefit of \u03b2-arrestin-biased 5-HT2A R agonists?",
        "options": {
            "A": "Enhancing visual acuity",
            "B": "Inducing psychedelic experiences",
            "C": "Blocking psychedelic behaviors",
            "D": "Enhancing serotonin synthesis",
            "E": "Stimulating neuroplasticity",
            "F": "I don't know"
        }
    },
    "20": {
        "question": "What can head-twitch response (HTR) in mice predict?",
        "options": {
            "A": "Liver toxicity in humans",
            "B": "Psychedelic potential in humans",
            "C": "Weight gain due to drug use",
            "D": "Social anxiety levels",
            "E": "Cognitive decline",
            "F": "I don't know"
        }
    },
    "21": {
        "question": "Which component was vital to predicting psychedelic potential of ligands?",
        "options": {
            "A": "Molecular weight of the ligand",
            "B": "Skin permeability",
            "C": "5-HT2A receptor Gq-efficacy threshold",
            "D": "Degree of serotonergic binding",
            "E": "NK receptor affinity",
            "F": "I don't know"
        }
    },
    "22": {
        "question": "What is one reason certain 5-HT2A partial agonists are considered non-psychedelic?",
        "options": {
            "A": "Low Gq-efficacy",
            "B": "High dopamine reuptake",
            "C": "Increased heart rate",
            "D": "Increased Gq-efficacy",
            "E": "High \u03b2-arrestin2 recruitment",
            "F": "I don't know"
        }
    },
    "23": {
        "question": "In the study, why were certain compounds used to block in vivo psychedelic behaviors?",
        "options": {
            "A": "To assess their ability to downregulate 5-HT",
            "B": "To measure behavioral anxiety",
            "C": "To determine receptor desensitization",
            "D": "To test for cognitive load",
            "E": "To stop visual perception changes",
            "F": "I don't know"
        }
    },
    "24": {
        "question": "What method was used to synthesize the N-benzyl compounds?",
        "options": {
            "A": "Hydrolysis",
            "B": "Oxidation",
            "C": "Reductive amination",
            "D": "Electrolysis",
            "E": "Nitration",
            "F": "I don't know"
        }
    },
    "25": {
        "question": "What did high Gq efficacy in mice correlate with, according to the study?",
        "options": {
            "A": "Decreased immune response",
            "B": "Enhanced vision",
            "C": "Increased head-twitch response",
            "D": "Increased feeding behavior",
            "E": "Decreased auditory response",
            "F": "I don't know"
        }
    },
    "26": {
        "question": "Which receptor agonist did not show psychedelic potential in the study?",
        "options": {
            "A": "Psilocin",
            "B": "DMT",
            "C": "5-MeO-DMT",
            "D": "LSD",
            "E": "Lisuride",
            "F": "I don't know"
        }
    },
    "27": {
        "question": "Why is 5-HT2A receptor Gq-efficacy important in drug development?",
        "options": {
            "A": "To develop effective antidepressants",
            "B": "To improve cardiovascular drugs",
            "C": "To modulate psychedelic effects",
            "D": "To treat metabolic disorders",
            "E": "To enhance cognitive functions",
            "F": "I don't know"
        }
    },
    "28": {
        "question": "What was demonstrated by \u03b2-arrestin-biased agonists in the study?",
        "options": {
            "A": "Psychosis treatment potential",
            "B": "Increased dopamine stimulation",
            "C": "Reduction in heart-twitch response",
            "D": "Lowering of blood pressure",
            "E": "Enhanced noradrenaline release",
            "F": "I don't know"
        }
    },
    "29": {
        "question": "How did \u03b2-arrestin-biased 5-HT2A R agonists affect repetitive administration outcomes?",
        "options": {
            "A": "Prevention of tolerance",
            "B": "Induction of receptor upregulation",
            "C": "Induced tolerance",
            "D": "Stimulation of appetite",
            "E": "Induction of sleep",
            "F": "I don't know"
        }
    },
    "30": {
        "question": "What action did \u03b2-arrestin-biased 5-HT2A R agonists have on PCP-induced behaviors?",
        "options": {
            "A": "Enhanced hyperactivity",
            "B": "Blocked hyperactivity",
            "C": "Caused sedation",
            "D": "Induced aggression",
            "E": "Induced calmness",
            "F": "I don't know"
        }
    },
    "31": {
        "question": "What method was used to predict electronic properties of N-benzyl-phenethylamines?",
        "options": {
            "A": "Infrared Spectroscopy",
            "B": "HPLC Analysis",
            "C": "Hammett \u03c3 constants",
            "D": "Mass Spectrometry",
            "E": "UV-Vis Spectroscopy",
            "F": "I don't know"
        }
    },
    "32": {
        "question": "What is a key characteristic of \u03b2-arrestin-biased agonists at the 5-HT2A receptor?",
        "options": {
            "A": "Prominent psychedelic effects",
            "B": "Induction of serotonin excess",
            "C": "Poor receptor desensitization",
            "D": "Reduced neuroplasticity",
            "E": "Potential receptor downregulation",
            "F": "I don't know"
        }
    },
    "33": {
        "question": "What was the key residue involved in distinguishing ligand bias?",
        "options": {
            "A": "Phe339",
            "B": "Asp351",
            "C": "Trp337",
            "D": "W3366",
            "E": "Lys313",
            "F": "I don't know"
        }
    },
    "34": {
        "question": "How did the 25N-N1-Nap(16) compound affect W3366 in terms of 5-HT2A R?",
        "options": {
            "A": "Activated Gq and \u03b2-arrestin equally",
            "B": "Forced W3366 into a unique rotamer conformation",
            "C": "Deactivated receptor selectivity",
            "D": "Promoted dopamine release",
            "E": "Caused receptor downregulation",
            "F": "I don't know"
        }
    },
    "35": {
        "question": "Why did the study use molecular dynamics simulations?",
        "options": {
            "A": "To measure liver enzyme activity",
            "B": "To predict solubility and stability",
            "C": "To explore dynamic interactions of ligands with 5-HT2A",
            "D": "To enhance treatment protocols for anxiety",
            "E": "To identify gene expression patterns",
            "F": "I don't know"
        }
    },
    "36": {
        "question": "What effect did mutations in W3366 have on Gq-efficacy in the study?",
        "options": {
            "A": "No change in efficacy",
            "B": "Complete loss of Gq-activation",
            "C": "Improved serotonin release",
            "D": "Increased cognitive load",
            "E": "Neutralized receptor downregulation",
            "F": "I don't know"
        }
    },
    "37": {
        "question": "Why was the head-twitch response used as a measure in this study?",
        "options": {
            "A": "To study appetite regulation",
            "B": "To predict psychedelic effects in humans",
            "C": "To study depression symptoms",
            "D": "To evaluate metabolism changes",
            "E": "To assess cardiovascular health",
            "F": "I don't know"
        }
    },
    "38": {
        "question": "What kind of agonism is associated with reduced psychedelic potential?",
        "options": {
            "A": "Balanced Gq and \u03b2-arrestin2 agonism",
            "B": "Biased Gq agonism",
            "C": "Biased \u03b2-arrestin2 agonism",
            "D": "Partial dopamine agonism",
            "E": "Enhanced G12 agonism",
            "F": "I don't know"
        }
    },
    "39": {
        "question": "Which assay was used to confirm ligand-induced receptor conformational states?",
        "options": {
            "A": "Western Blotting",
            "B": "NanoBit Internalization Assay",
            "C": "Southern Blot",
            "D": "Fluorescence Microscopy",
            "E": "Electron Microscopy",
            "F": "I don't know"
        }
    },
    "40": {
        "question": "What threshold parameter is critical for psychedelic-like effects?",
        "options": {
            "A": "50% \u03b2-arrestin2 recruitment",
            "B": "90% Gq-efficacy",
            "C": "70% Gq-efficacy",
            "D": "60% serotonin synthesis",
            "E": "75% dopamine uptake inhibition",
            "F": "I don't know"
        }
    },
    "41": {
        "question": "What prediction could be made using the 5-HT2A R Gq-efficacy data?",
        "options": {
            "A": "Potential hallucinogenic effects",
            "B": "Immune response modulation",
            "C": "Bronchodilation potential",
            "D": "Increased muscle relaxation",
            "E": "Enhanced fat metabolism",
            "F": "I don't know"
        }
    },
    "42": {
        "question": "What was the purpose of using 3- and 2-position substitutions on the N-benzyl ring?",
        "options": {
            "A": "To enhance water solubility",
            "B": "To improve protein binding",
            "C": "To modulate ligand bias and receptor affinity",
            "D": "To decrease chemical stability",
            "E": "To increase heart rate",
            "F": "I don't know"
        }
    },
    "43": {
        "question": "What outcome was observed with \u03b2-arrestin-biased ligands in relation to HTR?",
        "options": {
            "A": "Increased head-twitch response",
            "B": "No induction of HTR",
            "C": "Decreased serotonin activity",
            "D": "Enhanced liver toxicity",
            "E": "Increased blood pressure",
            "F": "I don't know"
        }
    },
    "44": {
        "question": "How does \u03b2-arrestin-biased agonism potentially affect receptor expression?",
        "options": {
            "A": "By increasing long-term receptor efficacy",
            "B": "By inducing receptor desensitization",
            "C": "By preserving basal activity",
            "D": "By driving receptor upregulation",
            "E": "By enhancing receptor transcription",
            "F": "I don't know"
        }
    },
    "45": {
        "question": "What is the effect of subthreshold Gq-efficacy on psychedelic potential?",
        "options": {
            "A": "It increases blood oxygen levels",
            "B": "It enhances psychedelic effects",
            "C": "It prevents head-twitch response and psychedelic effects",
            "D": "It induces high heart rates",
            "E": "It promotes serotonin binding",
            "F": "I don't know"
        }
    },
    "46": {
        "question": "What would increase the selectivity of a 5-HT2A agonist according to the study?",
        "options": {
            "A": "Removing 2-halogen atoms",
            "B": "Adding a methoxy group at C5'",
            "C": "Exchanging N-benzyl with bulkier rings such as bi-aryl",
            "D": "Increasing serotonin availability",
            "E": "Enhancing lipophilicity",
            "F": "I don't know"
        }
    },
    "47": {
        "question": "What was a novel observation regarding the toggle switch W3366 in the simulations?",
        "options": {
            "A": "Its static interaction with ligands",
            "B": "It adopts a unique rotamer conformation when interacting with \u03b2-arrestin-biased agonists",
            "C": "Its tendency to remain unchanged",
            "D": "Its strong preference for inactive receptors",
            "E": "It promotes receptor hyperactivity",
            "F": "I don't know"
        }
    },
    "48": {
        "question": "How do mutations help understand ligand activity at the 5-HT2A receptor?",
        "options": {
            "A": "They destabilize receptor structure",
            "B": "They confirm ligand binding site interactions",
            "C": "They cause immediate receptor downregulation",
            "D": "They stop receptor activation altogether",
            "E": "They promote dopamine synthesis",
            "F": "I don't know"
        }
    },
    "49": {
        "question": "Which feature of 5-HT2A receptor agonists correlates with HTR magnitude?",
        "options": {
            "A": "\u03b2-arrestin2 pathway efficacy",
            "B": "Gq-efficacy",
            "C": "Dopamine receptor binding",
            "D": "Cortisol release patterns",
            "E": "Serotonin transporter inhibition",
            "F": "I don't know"
        }
    },
    "50": {
        "question": "What does the HTR assay help differentiate in terms of 5-HT2A receptor agonists?",
        "options": {
            "A": "Pain experience levels",
            "B": "Non-psychedelic versus psychedelic potential",
            "C": "Gender differences in response",
            "D": "Heart rate changes",
            "E": "Immune responses",
            "F": "I don't know"
        }
    }
}